Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: results of a pilot study
Authors:
Open Access
- 1 August 2009
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 161 (2) , 363-368
Abstract
Objective It has been reported that hypoactive sexual desire disorder (HSDD) affects one-third of transsexual women (defined as postoperative male-to-female transsexuals) receiving estrogen replacement whose bioavailable androgen levels are lower than in ovulating women and comparable with those in surgically postmenopausal women. The aim of this study was to evaluate the efficacy of transdermal testosterone treatment and of oral dydrogesterone in transsexual women with HSDD receiving estrogens. Methods Seven transsexual women with HSDD were treated with a testosterone patch and nine transsexual women with HSDD were treated with oral dydrogesterone over 24 weeks. The primary end point was the change in the brief profile of female sexual function (B-PFSF) score. Secondary end points were changes in hormonal parameters and side effect assessments. Results A significant increase in total testosterone and free testosterone levels was observed in the group receiving transdermal testosterone. At 24 weeks, there was a significant improvement in the B-PFSF score showing an improvement in sexual desire among transsexual women treated with the testosterone patch, whereas no change in the B-PFSF score was observed in transsexual women treated with oral dydrogesterone. No side effects were reported. Conclusions In this pilot study, sexual desire in transsexual women improved significantly after treatment with the testosterone patch, without noticeable side effects.Keywords
This publication has 28 references indexed in Scilit:
- Influence of Body Mass Index on Measured and Calculated Androgen Parameters in Adult Women with Hirsutism and PCOSExperimental and Clinical Endocrinology & Diabetes, 2007
- Evaluation of Biochemical Hyperandrogenemia and Body Mass Index in Women Presenting with AmenorrheaExperimental and Clinical Endocrinology & Diabetes, 2007
- Development and validation of a new screening tool for hypoactive sexual desire disorder: The Brief Profile of Female Sexual Function©(B-PFSF©)Gynecological Endocrinology, 2007
- Effects on the Male Endocrine System of Long-term Treatment with Gonadotropin-releasing Hormone Agonists and Estrogens in Male-to-Female TranssexualsHormone and Metabolic Research, 2006
- Safety and Efficacy of a Testosterone Patch for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women: a Randomized, Placebo-Controlled TrialJournal of Urology, 2006
- Endocrine Treatment of Male-to-Female Transsexuals Using Gonadotropin-Releasing Hormone AgonistExperimental and Clinical Endocrinology & Diabetes, 2005
- Women with low libido: correlation of decreased androgen levels with female sexual function indexInternational Journal Of Impotence Research, 2004
- Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: Part B: Reduced serum androgen levels in healthy premenopausal women with complaints of sexual dysfunctionInternational Journal Of Impotence Research, 2004
- Physical and hormonal evaluation of transsexual patients: A longitudinal studyArchives of Sexual Behavior, 1986
- Changes in sexual behavior as a function of plasma sex steroid levels in post-menopausal womenMaturitas, 1985